Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT00415324 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: eribulin mesylate
DRUG: cisplatin
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)